TCR Activator Raji Cell Line
Recombinant Raji cell line stably expressing an engineered, membrane-bound T cell receptor (TCR) activator. The cell line has been functionally validated in a co-culture assay for activation of the NFAT Reporter Jurkat cells.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Name | Ordering Information |
Thaw Medium 2 | BPS Bioscience #60184 |
Growth Medium 2D | BPS Bioscience #79639 |
The cell line has been screened to confirm the absence of Mycoplasma species.
The T Cell Receptor (TCR) is a heterodimer protein found at the surface of T cells, which is stimulated upon binding to Major Histocompatibility Complex (MHC)/peptide complexes and triggers a signaling cascade that leads to the activation of transcription factors involved in the upregulation and secretion of cytokines, T cell proliferation, and cell differentiation into effector and memory cells.
The Raji line was established from a Burkitt's lymphoma patient. Raji cells constitutively express B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T-cells. Raji Recombinant Cell Lines are biologically relevant targets for CAR-T or NK cells targeting CD19, CD20, or CD22.
When co-cultured with T cells, the engineered TCR activator cells stimulate the TCR on T cells, leading to activation of downstream signaling pathways and biological responses such as proliferation.